BioInsights - Considerations for demonstrating comparability of AAV processes

Considerations for demonstrating comparability of AAV processes

Cell & Gene Therapy Insights 2022; 8(3), 475–479

DOI: 10.18609/cgti.2022.071

Published: 25 April 2022
Viewpoint
Laura Giersch

“...it is important to try to stockpile material during different virus productions in order to ensure that if a comparability study is required one day, the requisite material will be available.”